Drug manufacturers could receive more information on FDA's intentions for collecting quality data in the coming months.
The only addition in FDA's Aug. 8 guidance agenda update for calendar year 2016 was a revised draft...
It's the only addition to the agency's 2016 agenda.
Drug manufacturers could receive more information on FDA's intentions for collecting quality data in the coming months.
The only addition in FDA's Aug. 8 guidance agenda update for calendar year 2016 was a revised draft...